Cannabidiol (CBD) for Canine Idiopathic Epilepsy: What the Controlled Trials Show

Bottom line

• In dogs with drug-resistant idiopathic epilepsy, cannabidiol (CBD) added to existing antiseizure drugs produced a statistically significant reduction in overall seizure frequency versus placebo in two randomized controlled trials and one open-label cohort — but the proportion of dogs reaching the conventional 50%-responder threshold was not significantly different from placebo in the controlled studies.[1][2][3]
• The effect is best characterized as a modest, adjunctive reduction in seizure burden, not a stand-alone replacement for established antiseizure drugs.[1][2]
• A consistent, reproducible finding across the canine epilepsy studies is an increase in serum alkaline phosphatase (ALP); baseline and periodic liver enzyme monitoring is warranted, especially alongside other antiseizure drugs.[1][2][3]
• CBD is metabolized hepatically and can engage cytochrome P450-mediated interactions, so concurrent antiseizure medications and other hepatically cleared drugs deserve attention.[4][5]
• Outside epilepsy, CBD's evidence for canine osteoarthritis pain is unsettled — an oral full-spectrum extract was null at 90 days while a liposomal subcutaneous formulation improved pain in a small pilot — reinforcing that benefit is not established and appears formulation- and route-dependent.[6][7]
• Evidence quality remains limited (small cohorts, short follow-up, heterogeneous products), and there is no FDA- or EMA-approved veterinary CBD product for canine epilepsy; product concentration, purity, and contaminant profiles are not standardized.[3][4]

Drug facts

• Class: Phytocannabinoid (non-psychotropic cannabinoid); investigational adjunctive antiseizure agent in dogs.
• Mechanism: Multi-target; the anticonvulsant mechanism is not fully established. CBD is non-psychotropic and distinct from tetrahydrocannabinol (THC).[4]
• Route: Oral (CBD-infused oils in the controlled canine epilepsy trials). Investigational long-acting subcutaneous liposomal formulations have been studied for pain, not epilepsy.[1][2][7]
• Indication: No FDA or EMA approval for epilepsy in dogs. Use is off-label, adjunctive, and investigational.
• Approval: No approved veterinary CBD product for canine epilepsy as of July 2026. (In human medicine, a purified CBD oral solution is approved for specific epilepsy syndromes; that approval does not extend to veterinary species.)
• Contraindications / precautions: No veterinary label defines contraindications. Given hepatic metabolism and CYP450 interaction potential, exercise caution with concurrent hepatically cleared drugs and in patients with hepatic compromise; monitor liver enzymes.[4][5]
• Reported adverse effects in dogs: Increased serum ALP; gastrointestinal signs (decreased appetite, vomiting); ataxia at higher exposures.[1][2][3]

What the evidence shows

Efficacy: does CBD reduce seizures? (randomized controlled trials)

The first randomized, blinded, placebo-controlled clinical trial of oral CBD as an add-on for canine idiopathic epilepsy enrolled 26 client-owned dogs with intractable disease, randomized to CBD-infused oil or placebo for 12 weeks in addition to existing antiseizure treatment.[1] Dogs in the CBD group had a significant reduction in seizure frequency compared with placebo, with a reported median change of 33%. Notably, the proportion of dogs classified as responders (at least a 50% decrease in seizure activity) was similar between the CBD and placebo groups, and plasma CBD concentrations correlated with the degree of seizure-frequency reduction. The authors concluded that, given that correlation, further research was warranted to determine whether higher exposure would achieve a 50%-responder benefit.[1]

A subsequent double-blinded, placebo-controlled crossover study examined this dose-response question directly in 51 dogs with drug-resistant idiopathic epilepsy, each required to have at least two seizures per month while on at least one antiseizure drug.[2] A lower daily dosage met futility requirements after 12 dogs, and a higher daily dosage was used in the remaining 39 dogs. At the higher dosage, the decrease in total seizure frequency was significant compared with placebo: a 24.1% decrease in seizure days occurred with CBD versus a 5.8% increase with placebo. As in the earlier trial, there was no significant difference in the number of responders between phases. Liver enzyme activity increased at both dosages, and decreased appetite and vomiting were more common during the CBD phase.[2]

As of July 2026, the two controlled trials point in the same direction: CBD as an adjunct produces a real but modest reduction in overall seizure burden, while the harder endpoint of a 50%-responder rate has not been reproducibly separated from placebo. This nuance is central to setting client expectations.

Open-label and pilot cohort data

A prospective pilot study in 13 dogs with refractory epilepsy, all receiving multiple concurrent antiseizure drugs, used a single-arm pretest-posttest design with a deliberate start-low, go-slow titration.[3] The investigators reported a significant overall reduction in seizure frequency, with the median falling from 11 to 5 seizures, and noted that 61.5% of dogs achieved at least a 50% reduction in seizure frequency in this uncontrolled setting. The number of seizure clusters also decreased significantly. Most hematologic and renal parameters remained stable, but alkaline phosphatase increased significantly, and owners reported improved quality of life.[3] Because this was an uncontrolled cohort, the higher responder figure cannot be directly compared with the placebo-controlled trials; the cluster-seizure and quality-of-life signals are nonetheless consistent with the controlled data and worth tracking in future work.

Safety and adverse effects

Across the canine epilepsy studies, the most consistent laboratory finding is an increase in serum alkaline phosphatase, reported in the foundational trial, the dose-response crossover, and the refractory-epilepsy pilot.[1][2][3] Gastrointestinal signs (decreased appetite, vomiting) and, at higher exposures, ataxia have also been described.[1][2] These findings support baseline and periodic liver enzyme monitoring during CBD use, especially when CBD is layered onto other antiseizure drugs that themselves affect the liver.

Product quality is a separate safety consideration. The lack of a standardized veterinary product means that label claims, actual cannabinoid content, and contaminant profiles vary widely; this variability is a recognized limitation of the current evidence base.[4]

Drug interactions and hepatic metabolism (contested emphasis, converging conclusion)

Two lines of review evidence bear on interaction risk, and they differ mainly in scope rather than conclusion. A comparative veterinary review of the endocannabinoid system and phytocannabinoids summarizes the pharmacokinetics, efficacy, and tolerability of cannabis derivatives — predominantly CBD-containing products — across dogs, cats, horses, and other species of veterinary interest, and frames hepatic metabolism as central to CBD disposition in companion animals.[4] A 2026 clinical-pharmacology review of cannabinoids and drug-drug pharmacokinetic interactions catalogues how major cannabinoids, including CBD, can alter the absorption, distribution, metabolism, and excretion of co-administered drugs — including antiseizure agents — via cytochrome P450 pathways.[5]

The tension between these sources is one of applicability, not direction: the veterinary review is species-appropriate but broad, while the 2026 interaction review is mechanistically detailed but human-focused in its examples, so its species-specific thresholds do not transfer to dogs.[5] Neutral synthesis: both agree that CBD undergoes extensive first-pass hepatic metabolism and can modulate CYP450 activity, and this converges with the reproducible ALP elevation seen in the canine epilepsy trials — so concurrent antiseizure drugs and other hepatically cleared medications warrant attention. Neither review supports a specific veterinary dose adjustment; interaction management should be confirmed against a current formulary and clinical judgment.[4][5]

Multimodal / off-label use: CBD for canine osteoarthritis pain

Clinicians who use CBD for epilepsy are frequently asked about it for concurrent osteoarthritis pain, so the adjacent evidence is worth knowing — and it is genuinely mixed. As of 2025, a double-blind, randomized trial of an oral full-spectrum cannabis extract versus placebo in 17 dogs with osteoarthritis over 90 days did not significantly reduce pain on the Helsinki Chronic Pain Index (a 2.4-point reduction versus placebo was observed at 90 days), though treatment was reported as safe with only mild, self-resolving side effects.[6] In contrast, a randomized, blinded crossover pilot of a liposomal synthetic CBD given subcutaneously versus placebo in eight dogs with radiographically confirmed osteoarthritis significantly improved pain and lameness scores and behavior; plasma CBD was detectable for up to four weeks after a single injection, with adverse effects limited to a couple of days of fever and minor-to-moderate local swelling that resolved spontaneously.[7]

The two osteoarthritis trials illustrate why this evidence remains unsettled: designs, formulations, and routes differ substantially, one primary endpoint was negative and the other positive, both cohorts were small, and both were short in duration. Oral CBD's poor bioavailability from extensive first-pass hepatic metabolism is part of the rationale for the liposomal slow-release approach.[7] Neutral synthesis: across indications, CBD shows acceptable short-term tolerability paired with as-yet-uncertain efficacy; for osteoarthritis it is not a substitute for evidence-based analgesics, and any product, route, and dose should be confirmed against a current formulary.[6][7]

Contraindications, precautions & PK

• Pharmacokinetics: Oral CBD undergoes extensive first-pass hepatic metabolism, giving poor oral bioavailability; hepatic metabolism is central to its disposition in dogs.[4][7] A single subcutaneous liposomal dose produced detectable plasma CBD for up to four weeks in the canine osteoarthritis pilot, illustrating markedly different exposure kinetics by formulation and route.[7]
• Hepatic signal / monitoring: Reproducible ALP elevation across canine epilepsy studies supports baseline and periodic liver enzyme monitoring, particularly when CBD is combined with other hepatically metabolized antiseizure drugs.[1][2][3]
• Interactions: CYP450 modulation creates potential for pharmacokinetic interactions with co-administered, hepatically cleared drugs; management is not defined by a specific veterinary dose adjustment and should be individualized against a current formulary.[4][5]
• Product variability: Non-standardized veterinary products mean label concentration, purity, and contaminant profiles are unreliable — a material precaution when selecting any product.[4]
• Approval status: No FDA/EMA veterinary approval for canine epilepsy; all use is off-label and investigational.

Practical decision support

For dogs whose seizures remain inadequately controlled despite appropriately dosed conventional antiseizure drugs, the current evidence positions CBD as an investigational adjunct that may modestly reduce seizure burden in some patients — not as a replacement for established therapy. The controlled trials support honest client communication: a measurable reduction in overall seizure frequency is plausible, but a halving of seizures (the 50%-responder benchmark) has not been reproducibly demonstrated against placebo.[1][2]

Where a clinician elects a trial of CBD:

• Obtain baseline liver enzymes and monitor periodically, given the reproducible ALP signal — especially in patients already on hepatically metabolized antiseizure drugs.[1][2][3]
• Review concurrent medications for CYP450-mediated interaction potential with hepatically cleared drugs; do not extrapolate human-specific interaction thresholds to dogs.[4][5]
• Scrutinize the product, since cannabinoid content and contaminants are not standardized across the veterinary market.[4]
• If the owner is also asking about osteoarthritis pain, set expectations that CBD's analgesic benefit is unproven and formulation-dependent, and keep evidence-based analgesics as the mainstay.[6][7]

Specific products, exposures, and titration schedules should be confirmed against a current formulary and the clinician's own judgment rather than generalized from any single study; this page does not recommend a dose.

Frequently Asked Questions

Does CBD reduce seizures in dogs with epilepsy? In two randomized placebo-controlled trials, CBD added to existing antiseizure drugs significantly reduced overall seizure frequency versus placebo (median ~33% in one trial; a 24.1% reduction in seizure days versus a 5.8% increase on placebo in another). However, the proportion of dogs reaching a 50% reduction was not significantly different from placebo in the controlled studies.[1][2]

Is CBD a replacement for conventional antiseizure drugs in dogs? No. The current evidence supports CBD only as an investigational adjunct in drug-resistant cases, not as a stand-alone replacement for established antiseizure drugs.[1][2]

What monitoring is needed when using CBD in epileptic dogs? A reproducible finding across canine studies is an increase in serum alkaline phosphatase (ALP). Baseline and periodic liver enzyme monitoring is warranted, especially when CBD is combined with other antiseizure drugs.[1][2][3]

Can CBD interact with other antiseizure medications? CBD undergoes extensive hepatic metabolism and can modulate cytochrome P450 enzymes, so concurrent antiseizure drugs and other hepatically cleared medications deserve attention. Confirm interactions and any dosing against a current formulary.[4][5]

Is there an FDA-approved CBD product for canine epilepsy? No. As of July 2026 there is no FDA- or EMA-approved veterinary CBD product for canine epilepsy. Available products are not standardized for concentration, purity, or contaminants, which is a recognized limitation of the evidence base.[4]

What adverse effects have been reported with CBD in dogs? Reported effects include increased serum ALP, gastrointestinal signs such as decreased appetite and vomiting, and ataxia at higher exposures.[1][2][3]

Does CBD relieve osteoarthritis pain in dogs? The evidence is mixed. A double-blind trial of an oral full-spectrum extract in 17 dogs found no significant reduction in pain on the Helsinki Chronic Pain Index over 90 days, while a small crossover pilot of a long-acting subcutaneous liposomal CBD significantly improved pain and lameness scores versus placebo. Results may depend on formulation and route, and CBD is not a substitute for evidence-based analgesics.[6][7]

Is CBD safe for dogs over the short term? Across canine trials, CBD has shown acceptable short-term tolerability. In the osteoarthritis studies, the oral extract caused only mild, self-resolving side effects, and the liposomal injection caused a couple of days of fever and minor-to-moderate local swelling that resolved spontaneously. Long-term safety has not been established, and liver enzyme elevation is a consistent signal.[3][6][7]

Changelog

• 2026-06-20: First published.
• 2026-07-06: Consolidated hub. Folded in the CBD drug-interactions dispatch (adds Papakyriakopoulou 2026 clinical-pharmacology interaction review) and the CBD canine-osteoarthritis-pain dispatch (adds Griebeler 2025 oral-extract RCT and Shilo-Benjamini 2025 liposomal-injectable crossover pilot). Reorganized evidence by clinical question and added dedicated PK/interactions and decision-support sections.